There is an unmet need in later lines of CML1-3

Using line after line of ATP-competitive TKIs may lead to increased failure rates1-3

  • New mutations from ATP-competitive TKI use can result in limited sensitivity to some TKIs4
  • Potential resistance or intolerance in second- and third-line may result in poorer efficacy outcomes and increased risk of discontinuation1,5
 
8-year overall survival is 83% in first line and 22% OS in third line (based on a retrospective, single-center analysis)

 

Line after line of ATP-competitive TKI treatments leave patients with few options6-10

  • There is a need to understand off-target activities11,12
  • Patients with CML may experience intolerance in later lines6-10
Up to 55% of patients with CML in ≥3rd line

Assessing different patient scenarios in later lines of CML

Consider a patient experiencing potential drug resistance

Consider a patient experiencing potential drug resistance

View a profile of a patient experiencing a borderline response

View a profile of a patient experiencing a borderline response

Review a patient having difficulty tolerating treatment

Review a patient having difficulty tolerating treatment

Hear from patients and medical experts.

 

ATP, adenosine 5’-triphosphate; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

References: 1. Garg RJ, Kantarjian H, O'Brien S, et al. Blood. 2009;114(20):4361-4368. 2. Bosi GR, Fogliatto LM, Costa TEV, et al. Hematol Transfus Cell Ther. 2019;41(3):222-228. 3. Iacob RE, Zhang J, Gray NS, et al. PLoS One. 2011;6(1):e15929. 4. Soverini S, Gnani A, Colarossi S, et al. Blood. 2009;114(10):2168-2171. 5. Ibrahim AR, Paliompeis C, Bua M, et al. Blood. 2010;116(25):5497-5500. 6. Cortes JE, Khoury HJ, Kantarjian HM, et al. Am J Hematol. 2016;91(12):1206-1214. 7. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. N Engl J Med. 2013;369(19):1783-1796. 8. Kim TD, Schwarz M, Nogai H, et al. Thyroid. 2010;20(11):1209-1214. 9. Quintás-Cardama A, Kantarjian H, O'brien S, et al. J Clin Oncol. 2007;25(25):3908-3914. 10. Cortes J, Mauro M, Steegmann JL, et al. Am J Hematol. 2015;90(4):E66-E72. 11. Fabian MA, Biggs WH III, Treiber DK, et al. Nat Biotechnol. 2005;23(3):329-336. 12. Karaman MW, Herrgard H, Treiber DK, et al. Nat Biotechnol. 2008;26(1):127-132. 13. Ongoren S, Eskazan AE, Suzan V, et al. Hematology. 2017;23(4):212-220. 14. Giles FJ, Abruzzese E, Rosti G, et al. Leukemia. 2010;24(7):1299-1301.

This site is for US health care professionals only.

Use of website is governed by the Terms of Use and Privacy Policy

Copyright © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.

 

9/21 152562